Guillain-Barre syndrome: Guillain-BarrC) syndrome (GBS) is the term used to describe a spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients. GBS is clinically heterogeneous and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS; see these terms) and some other regional variants.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
598 |
4. Check minimum number of eventsNone |
598 |
5. Include endpointsNone |
598 |
6. Filter based on genotype QC (FinnGen only) |
575 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G61
- Name in latin
- Syndroma Guillain-Barré
Similar endpoints
↥List of similar endpoints to
Guillain-Barre syndrome
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4635 | 2063 | 2535 |
| Only index persons | 3894 | 1777 | 2117 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.06 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 50.92 | 49.00 | 52.39 |
| Only index persons | 48.14 | 46.19 | 49.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 575 | 261 | 314 |
| Unadjusted period prevalence (%) | 0.12 | 0.09 | 0.14 |
| Median age at first event (years) | 52.59 | 48.78 | 55.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 598
- Matched controls
- 5980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G61.0
ICD-10 Finland
Guillain-Barré syndrome
4503599627370496.0
307.7
508
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
88.1
170.0
90
12
TAB00
NOMESCO Finland
Lumbar puncture
13.2
128.1
135
129
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
28.1
104.0
72
29
G61.9
ICD-10 Finland
Inflammatory polyneuropathy, unspecified
341.5
61.6
61
*
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
+∞
60.5
57
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.6
55.5
120
255
35401
ICD-8 Finland
Polyneuritis and polyradiculitis, Polyradicultitis Guillain-Barré
+∞
55.1
52
*
3570A
ICD-9 Finland
Inflammatory and toxic neuropathy, Acute infective polyneuritis
+∞
52.9
50
*
N28
ICPC
Limited function/disability (N)
18.7
52.0
42
24
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
15.5
47.2
42
29
R20.2
ICD-10 Finland
Paraesthesia of skin
5.7
46.5
97
198
6BA02, ,
NOMESCO Finland
225.4
41.4
42
*
N29
ICPC
Neurological sympt/complt other
10.4
34.2
39
40
N03AX16
ATC
[U] pregabalin
3.0
31.6
193
826
ZX120
NOMESCO Finland
Intravenous
3.9
30.2
102
302
WW400
NOMESCO Finland
Plasmaferesis
317.7
30.1
30
*
N03AX12
ATC
[U] gabapentin; oral
3.2
29.9
150
572
R4120
NOMESCO Finland
Occupational therapy
4.5
29.9
79
195
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.0
28.9
91
256
N99
ICPC
Neurological disease other
26.9
27.8
38
15
G62.8
ICD-10 Finland
Other specified polyneuropathies
146.6
26.9
28
*
AA1AD
NOMESCO Finland
CT of head and brain
2.6
26.1
209
1015
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
10.1
25.2
29
30
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.5
25.0
33
41
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.7
24.7
60
138
G82.2
ICD-10 Finland
Paraplegia, unspecified
37.2
20.0
25
7
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
19.2
134
597
G35
ICD-10 Finland
Multiple sclerosis
8.4
18.9
25
31
N94
ICPC
Peripheral neuritis/neuropathy
98.0
17.7
19
*
G51.0
ICD-10 Finland
Bell palsy
5.6
16.5
32
60
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
5.7
15.9
30
55
R1250
NOMESCO Finland
Evaluation of functional capability
5.8
15.7
29
52
XF400
NOMESCO Finland
ECG with 12 standard connections
2.5
15.4
118
545
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.5
15.3
54
163
L28
ICPC
Limited function/disability (L)
2.4
14.4
116
548
N18
ICPC
Paralysis/weakness
6.6
14.2
23
36
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.9
14.1
73
277
L04AX01
ATC
azathioprine; systemic
3.9
12.6
38
103
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.4
12.3
96
445
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.9
11.9
35
93
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
66.3
11.6
13
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
11.3
116
602
R4110
NOMESCO Finland
Physiotherapy
1.9
11.3
176
1063
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
5.2
11.1
23
46
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
10.7
280
1979
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
111.9
10.4
11
*
N06AX21
ATC
duloxetine; oral
2.3
10.3
81
376
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
4.0
10.2
29
75
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
14.9
10.0
16
11
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.7
10.0
56
221
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
10.0
141
819
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.5
9.9
68
297
Z3226
NOMESCO Finland
Physiotherapist
2.0
9.8
120
663
N06AA09
ATC
amitriptyline; systemic
2.5
9.7
62
261
H02AB07
ATC
prednisone; oral
2.2
9.7
90
448
XA402
NOMESCO Finland
ENMG
4.4
9.7
24
56
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
+∞
9.4
9
*
R53
ICD-10 Finland
Malaise and fatigue
1.9
9.3
151
916
M48.0
ICD-10 Finland
Spinal stenosis
2.2
9.3
82
399
N02BF02
ATC
pregabalin; oral
3.0
9.3
42
148
H02AB06
ATC
prednisolone; systemic
1.7
8.9
279
2041
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.8
8.7
151
934
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.8
8.5
166
1061
GBB00
NOMESCO Finland
Tracheostomy
8.0
8.4
18
23
G63.2*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic polyneuropathy
+∞
8.3
8
*
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.7
8.2
43
164
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
33.8
8.1
10
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.7
8.1
177
1168
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
3.2
8.1
31
99
A28
ICPC
Limited function/disability NOS
2.0
8.0
100
554
N03AX09
ATC
lamotrigine; oral
2.9
8.0
37
132
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.3
7.9
30
95
C03CA01
ATC
furosemide; systemic
1.7
7.9
171
1124
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.8
7.9
40
150
ZXD05
NOMESCO Finland
Urgent procedure
1.7
7.9
183
1226
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.1
7.8
79
406
M54.1
ICD-10 Finland
Radiculopathy
3.2
7.8
30
96
2AB04, ,
NOMESCO Finland
45.6
7.7
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.3
7.5
61
287
G63.0*A69.2
ICD-10 Finland
Polyneuropathy (in) Lyme disease
81.1
7.4
8
*
G61
ICD-10 Finland
Inflammatory polyneuropathy
81.1
7.4
8
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
11.0
7.3
13
12
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.6
7.2
17
38
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.0
7.2
20
51
R20.8
ICD-10 Finland
Other and unspecified disturbances of skin sensation
8.1
7.1
15
19
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.0
7.1
78
413
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
2.6
6.9
41
167
E11.4
ICD-10 Finland
Type 2 diabetes mellitus, with neurological complications
4.2
6.9
18
44
N30.0
ICD-10 Finland
Acute cystitis
2.0
6.9
84
462
Z3231
NOMESCO Finland
Registered nurse
1.7
6.8
164
1104
5AB01, ,
NOMESCO Finland
40.5
6.8
8
*
109
Kela drug reimbursment
Multiple sclerosis
7.3
6.7
15
21
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
2.7
6.6
36
141
TKC20
NOMESCO Finland
Catheterisation of bladder
2.4
6.6
46
203
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
6.5
203
1453
NA7DM
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with 3 Tesla magnet
70.6
6.4
7
*
A87
ICPC
Complication of medical treatment
18.2
6.3
9
5
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
6.2
127
815
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.1
6.2
14
20
N03AE01
ATC
clonazepam; systemic
2.5
6.2
38
157
G82.5
ICD-10 Finland
Tetraplegia, unspecified
27.0
6.2
8
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
2.4
6.2
40
170
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
7.8
6.1
13
17
M03BX01
ATC
baclofen; systemic
3.8
6.1
18
48
T78.4
ICD-10 Finland
Allergy, unspecified
3.0
6.1
27
94
XKD06
NOMESCO Finland
Physiologic investigation of micturition
3.2
6.1
24
78
WX892
NOMESCO Finland
Monitored bed care
2.2
6.1
50
237
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
2.8
6.0
29
106
J01MA12
ATC
levofloxacin; systemic
1.8
6.0
107
661
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
140
102
17.62
157.15
1.3
1.2
3.84
3.73
mmol/l
0.36
134
95
96
47
24.14
129.32
1.1
1.1
—
—
—
0
0
122
105
14.34
123.44
1.4
1.2
9.88
9.09
e6/l
0.04
94
85
122
105
14.34
123.44
1.4
1.3
476.38
1113.34
e6/l
0.27
97
89
94
52
21.26
119.93
1.2
1.1
—
—
—
0
0
94
53
20.86
118.87
1.2
1.1
—
—
—
0
0
76
39
22.18
99.81
1.3
1.1
75.88
43.66
mg/l
1.74
68
33
66
34
21.70
86.29
1.2
1.0
—
—
—
0
0
48
21
24.76
66.75
1.2
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
50
26
20.89
64.78
1.2
1.2
—
—
—
0
0
143
319
5.58
63.11
2.7
2.4
19.00
19.44
au/ml
—
6
21
56
39
15.74
62.96
1.1
1.3
—
—
—
0
0
48
27
19.24
59.96
1.1
1.0
1.03
1.16
u/l
0.47
26
13
133
374
4.29
43.17
2.5
2.2
10.39
10.74
g/l
0.36
120
345
33
30
11.58
31.36
1.1
1.1
—
—
—
0
0
208
933
2.89
31.17
1.6
1.4
2.26
2.50
g/l
1.30
162
591
117
376
3.63
30.77
2.5
2.8
67.12
66.67
g/l
0.22
108
344
269
1387
2.71
30.67
2.7
2.0
801.80
299.11
u/l
0.44
255
1303
41
60
7.26
27.05
1.2
1.1
—
—
—
0
0
36
16
23.85
25.51
1.3
1.4
—
—
—
0
0
52
118
4.73
21.71
1.1
1.1
—
—
—
0
0
32
19
17.71
20.70
1.3
1.3
—
—
—
0
0
57
157
3.91
18.47
2.6
2.2
2.93
3.05
g/l
0.34
52
142
59
168
3.79
18.24
2.5
2.2
—
—
—
0
0
59
168
3.79
18.24
2.5
2.2
7.32
7.29
g/l
0.03
54
153
59
168
3.79
18.24
2.5
2.2
3.33
3.64
g/l
1.28
54
153
56
154
3.91
18.18
2.0
2.2
10.39
10.71
g/l
0.15
51
138
153
746
2.41
18.01
3.7
3.4
0.80
0.82
mmol/l
0.66
146
709
332
2273
2.04
15.99
8.3
5.7
57.96
57.05
%
0.71
318
2154
336
2311
2.04
15.97
8.5
5.9
27.33
27.81
%
0.32
322
2193
62
204
3.28
15.35
1.9
2.2
32.43
39.43
u/l
1.77
56
184
51
150
3.62
15.01
2.2
2.4
0.24
1.19
g/l
1.49
46
134
24
16
15.57
14.99
1.1
1.2
—
—
—
0
0
24
16
15.57
14.99
1.1
1.1
—
—
—
0
0
24
16
15.57
14.99
1.1
1.1
—
—
—
0
0
48
138
3.69
14.61
2.2
2.2
37.85
37.44
g/l
0.14
43
123
379
2771
2.00
14.59
12.0
9.1
4.11
4.12
e9/l
0.04
341
2433
23
15
15.89
14.50
1.1
1.1
—
—
—
0
0
18
6
30.86
13.95
1.1
1.5
—
—
—
0
0
23
17
14.02
13.82
1.1
1.1
—
—
—
0
0
22
15
15.17
13.67
1.1
1.0
—
—
—
0
0
378
2797
1.96
13.62
7.5
4.8
6.77
6.68
mmol/l
0.33
363
2616
16
5
32.81
12.62
1.1
1.4
—
—
—
0
0
16
6
27.33
12.10
1.3
1.2
—
—
—
0
0
17
8
21.82
12.06
1.2
1.4
—
—
—
0
0
118
605
2.18
11.90
7.3
6.0
1.02
1.03
mmol/l
0.15
111
563
15
5
30.71
11.69
1.1
1.6
—
—
—
0
0
269
1850
1.83
11.48
2.3
1.9
92.69
94.93
pmol/l
0.30
162
982
288
2024
1.82
11.42
6.3
4.9
34.26
35.68
g/l
3.38
272
1892
21
20
10.84
11.34
1.0
1.4
134.29
160.27
nmol/l
0.81
21
20
21
39
5.54
10.94
1.0
1.1
0.12
2.22
nmol/l
—
5
6
21
22
9.85
10.83
1.0
1.0
—
—
—
0
0
314
2289
1.78
10.80
9.9
6.8
1.21
1.21
mmol/l
0.21
270
1961
37
114
3.39
10.16
1.2
1.3
—
—
—
0
0
394
3102
1.79
10.11
6.0
4.2
73.20
1854.42
e6/l
—
10
52
290
2093
1.75
10.10
9.5
6.0
1.20
1.21
mmol/l
0.74
270
1918
174
1089
1.84
9.78
1.7
1.5
19.95
20.68
nmol/l
0.26
151
932
141
825
1.93
9.76
1.8
1.7
1124.85
1170.19
nmol/l
0.25
114
638
85
416
2.22
9.52
7.3
7.2
9.47
9.88
mmol/l
0.18
80
397
32
94
3.54
9.45
6.2
6.7
1699.13
209.57
iu/ml
—
8
14
166
1042
1.82
9.16
2.0
1.6
1.61
1.16
mg/l
0.58
134
800
15
12
12.78
8.90
1.1
1.1
—
—
—
0
0
245
1734
1.70
8.81
4.8
3.1
—
—
—
0
0
23
56
4.23
8.79
1.2
1.8
—
—
—
0
0
25
69
3.74
8.09
2.6
3.9
—
3459.62
—
0
8
173
1136
1.74
8.04
2.3
2.1
3.02
3.10
mg/l
0.18
136
968
43
169
2.66
7.77
1.3
1.2
5.12
2.33
u/ml
—
5
12
17
23
7.57
7.72
3.0
2.1
—
—
—
0
0
251
1848
1.62
7.40
2.6
2.3
76.30
76.13
nmol/l
0.03
230
1658
11
7
15.97
7.25
1.2
1.1
—
—
—
0
0
152
989
1.72
7.20
3.6
2.5
4.62
4.55
e6/l
0.04
142
894
10
5
20.30
7.15
1.1
1.4
—
—
—
0
0
80
429
2.00
7.02
2.5
2.0
334.39
379.67
nmol/l
1.32
72
399
48
210
2.40
6.97
1.6
2.2
1.63
1.53
g/l
0.34
43
183
422
3550
1.64
6.93
5.0
4.0
14.08
11.73
mm/h
2.30
394
3273
206
1468
1.62
6.82
4.7
3.1
32.47
111.54
e6/l
1.04
167
1129
188
1317
1.62
6.64
4.6
3.0
0.32
0.53
e6/l
0.98
151
984
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
37
147
2.62
6.57
2.7
2.4
0.30
0.33
u/ml
0.41
18
72
319
2536
1.55
6.47
6.7
6.4
10.98
11.68
umol/l
0.67
310
2427
77
421
1.95
6.38
5.7
3.6
1.68
1.89
mmol/l
0.21
67
339
26
87
3.08
6.30
1.3
1.2
44.90
32.98
u/ml
—
5
9
122
774
1.72
6.26
2.2
1.8
—
—
—
0
0
47
219
2.24
5.93
5.6
3.9
23.79
24.10
mmol/l
0.33
47
214
37
158
2.43
5.69
1.2
1.4
—
—
—
0
0
261
2025
1.51
5.68
3.0
2.7
279.08
136.73
ug/l
0.69
237
1880
89
532
1.79
5.59
2.2
1.8
—
—
—
0
0
428
3697
1.55
5.49
9.5
7.6
77.31
78.55
u/l
0.19
408
3492
33
141
2.42
5.08
1.4
1.8
—
—
—
0
0
90
555
1.73
5.07
11.9
7.8
1.87
1.00
mmol/l
1.46
74
447
17
50
3.47
5.06
1.3
1.9
—
—
—
0
0
62
343
1.90
4.97
1.9
1.6
—
—
—
0
0
24
89
2.77
4.90
1.1
1.1
—
—
—
0
0
118
790
1.62
4.86
1.3
1.3
36.51
37.30
iu/ml
0.02
30
248
87
538
1.72
4.85
2.1
1.8
—
—
—
0
0
278
2234
1.46
4.84
12.7
14.0
1.20
1.25
inr
0.42
82
650
22
79
2.85
4.76
1.3
1.3
—
—
—
0
0
22
79
2.85
4.76
1.3
1.3
—
—
—
0
0
119
805
1.60
4.69
3.8
2.7
1.07
0.91
e6/l
0.25
72
451
88
553
1.69
4.63
12.2
7.7
5.22
5.09
kpa
0.61
83
532
11
18
6.20
4.62
1.1
1.0
1465.09
1416.17
miu/ml
0.05
11
18
88
554
1.69
4.59
12.2
7.7
11.37
12.13
kpa
1.18
82
536
7
5
14.14
4.58
1.0
1.2
—
—
—
0
0
8
9
8.99
4.29
1.0
1.0
—
—
—
0
0
8
9
8.99
4.29
3.3
2.0
—
—
—
0
0
158
1162
1.49
4.23
3.2
2.4
—
—
—
0
0
23
91
2.59
4.18
1.4
1.5
—
—
—
0
0
142
1026
1.50
4.13
1.3
1.2
0.55
1.98
u/ml
2.36
32
285
52
293
1.85
3.97
5.2
3.9
2.30
1.68
mmol/l
0.85
41
215
27
119
2.33
3.93
1.6
1.6
—
—
—
0
0
128
916
1.51
3.88
4.5
3.8
500.07
313.24
ng/l
0.33
100
706
6
5
12.10
3.77
1.5
1.2
—
—
—
0
0
15
50
3.05
3.71
1.1
1.3
—
—
—
0
0
278
2311
1.38
3.66
4.6
3.5
0.02
0.00
estimate
0.42
55
479
106
739
1.53
3.63
2.4
2.4
12.11
13.29
umol/l
0.96
100
689
12
30
4.06
3.61
1.3
1.3
—
—
—
0
0
30
144
2.14
3.59
3.3
4.1
35.35
103.67
mg/l
0.93
24
120
30
144
2.14
3.59
3.3
4.1
31.74
35.54
mg/l
0.23
24
121
7
9
7.85
3.56
1.0
1.0
—
—
—
0
0
98
677
1.54
3.49
2.3
2.4
2.29
2.31
g/l
0.12
92
628
29
139
2.14
3.49
1.3
1.1
—
—
—
0
0
109
771
1.51
3.48
4.2
2.9
3.90
1.79
e6/l
0.78
62
419
71
455
1.64
3.47
1.7
2.2
0.21
0.21
g/l
0.04
62
432
35
183
1.97
3.36
1.8
1.7
—
—
—
0
0
13
38
3.47
3.33
1.1
1.1
—
—
—
0
0
194
1541
1.38
3.30
3.1
3.4
2.33
2.35
mmol/l
1.73
174
1362
21
90
2.38
3.28
1.5
1.6
—
—
—
0
0
21
90
2.38
3.28
1.5
1.6
—
—
—
0
0
369
3244
1.36
3.25
4.0
3.2
53.63
48.91
u/l
0.48
345
3062
26
123
2.16
3.24
1.5
1.6
—
—
—
0
0
19
79
2.45
3.16
1.5
1.5
—
—
—
0
0
12
35
3.48
3.12
1.1
1.1
—
—
—
0
0
275
2324
1.34
3.10
6.1
4.7
0.00
0.00
estimate
-0.00
55
447
91
636
1.51
3.08
2.3
2.4
22.16
23.57
%
0.42
78
554
13
41
3.22
3.07
1.2
1.4
—
—
—
0
0
13
41
3.22
3.07
1.9
3.6
—
—
—
0
0
66
430
1.60
3.04
2.6
2.2
12.12
13.44
nmol/l
0.69
60
387
87
604
1.52
3.03
11.4
7.0
104.30
104.33
mmol/l
0.02
87
604
129
971
1.42
2.98
1.9
1.7
443.60
430.61
pmol/l
0.18
108
830
27
136
2.03
2.90
1.4
1.1
—
—
—
0
0
276
2351
1.32
2.88
4.7
3.5
0.00
0.01
estimate
0.50
55
430
70
470
1.55
2.84
14.4
8.5
119.73
121.50
g/l
0.28
70
460
18
77
2.38
2.84
1.1
1.1
6.31
17.79
iu/ml
—
8
19
15
59
2.58
2.80
1.7
1.5
—
—
—
0
0
15
59
2.58
2.80
1.7
1.5
—
—
—
0
0
8
18
4.49
2.80
1.5
1.7
25.88
28.61
umol/l
—
8
18
174
1391
1.35
2.78
4.3
3.3
1287.43
243.17
mg/l
0.99
123
921
82
575
1.49
2.73
3.4
2.8
11.26
8.70
umol/l
0.25
70
497
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
7
14
5.05
2.73
1.0
1.0
127.86
138.79
%
—
7
14
16
66
2.46
2.73
1.3
1.6
—
—
—
0
0
70
475
1.54
2.72
4.7
3.1
—
—
—
0
0
395
3556
1.33
2.70
3.9
3.7
14.68
14.72
pmol/l
0.15
357
3226
26
133
2.00
2.69
1.4
1.3
—
—
—
0
0
19
86
2.25
2.66
1.7
1.6
91.71
111.71
u/ml
—
7
14
24
120
2.04
2.64
1.6
1.7
—
—
—
0
0
30
163
1.88
2.62
2.0
1.5
—
—
—
0
0
16
68
2.39
2.57
1.4
1.6
—
—
—
0
0
5
7
7.19
2.55
1.0
1.0
88.00
94.43
%
—
5
7
198
1636
1.31
2.49
3.6
3.3
29.99
32.60
u/l
0.93
185
1560
20
96
2.12
2.45
1.7
1.5
—
—
—
0
0
188
1546
1.32
2.44
3.4
2.5
70.13
111.27
u/l
0.35
176
1449
24
124
1.97
2.44
1.3
1.5
—
—
—
0
0
27
146
1.89
2.41
1.7
1.5
0.26
0.13
iu/ml
—
7
29
66
455
1.51
2.40
3.5
2.5
58.28
33.13
u/l
0.42
60
388
10
33
3.06
2.36
1.0
1.4
—
—
—
0
0
219
1845
1.30
2.36
4.6
3.6
29.33
35.55
ng/l
0.58
150
1272
468
4353
1.35
2.34
4.8
4.4
1.82
2.18
mu/l
0.72
431
3985
155
1251
1.32
2.28
3.4
2.7
2202.13
7275.59
umol/l
1.45
134
1106
31
179
1.77
2.27
1.2
1.3
38.11
25.83
iu/l
0.67
24
152
5
9
5.59
2.21
1.0
2.9
—
—
—
0
0
29
166
1.79
2.19
2.1
3.1
—
—
—
0
0
262
2279
1.27
2.14
3.3
2.6
—
—
—
0
0
22
116
1.93
2.13
2.0
1.8
6.40
6.84
iu/l
—
8
35
13
55
2.39
2.13
1.7
1.5
49.38
64.69
%
0.71
13
48
58
401
1.49
2.10
2.2
2.4
8.28
8.21
ug/l
0.01
53
359
8
25
3.23
2.10
1.4
2.7
2270.00
907.48
u/ml
—
8
25
23
124
1.89
2.10
1.6
1.3
—
—
—
0
0
19
96
2.01
2.07
1.3
1.3
245.31
257.84
u/ml
0.08
13
51
44
288
1.57
2.04
1.8
1.7
—
—
—
0
0
43
281
1.57
2.01
1.5
1.4
—
—
—
0
0
9
32
2.84
2.00
1.0
1.6
—
—
—
0
0
9
32
2.84
2.00
1.0
1.6
—
—
—
0
0
17
84
2.05
1.97
1.6
1.7
—
—
—
0
0
164
1359
1.28
1.96
3.2
3.1
1674.23
1345.12
ng/l
0.29
143
1169
77
572
1.40
1.93
4.8
4.5
32.12
31.73
%
0.08
52
397
37
236
1.61
1.92
1.6
1.3
—
—
—
0
0
82
617
1.38
1.90
1.9
1.8
1.44
1.46
%
0.14
69
546
508
4825
1.35
1.89
23.7
13.9
22.65
23.74
mg/l
0.30
433
3845
47
319
1.51
1.88
11.3
6.5
25.42
24.40
mmol/l
1.07
47
304
5
12
4.19
1.82
1.0
1.1
—
—
—
0
0
7
23
3.07
1.80
3.4
3.2
50828.57
36187.17
ug/l
—
7
23
178
1510
1.25
1.74
4.4
3.2
7.41
7.93
mmol/l
0.92
146
1271
10
40
2.52
1.67
1.2
1.2
—
—
—
0
0
10
41
2.46
1.65
1.2
1.2
—
—
—
0
0
11
49
2.27
1.64
1.7
1.6
—
—
—
0
0
517
4947
1.33
1.62
26.9
16.1
3.96
3.98
mmol/l
0.51
506
4812
5
14
3.59
1.62
4.2
1.5
—
—
—
0
0
5
14
3.59
1.62
1.8
1.1
0.92
2.52
mmol/l
—
5
14
173
1475
1.24
1.61
5.0
3.8
3.98
8.80
mg/mmol
2.92
118
941
515
4931
1.32
1.56
26.3
16.0
139.42
139.67
mmol/l
1.51
507
4803
43
299
1.47
1.56
1.2
1.2
141.35
145.33
iu/ml
0.02
22
121
17
93
1.85
1.53
2.1
1.6
—
—
—
0
0
15
79
1.92
1.50
1.3
1.1
—
—
—
0
0
13
65
2.02
1.49
1.7
1.5
—
—
—
0
0
7
28
2.52
1.45
1.4
1.7
—
—
—
0
0
18
103
1.77
1.42
1.3
1.3
—
—
—
0
0
9
40
2.27
1.40
1.2
1.2
—
—
—
0
0
9
41
2.21
1.37
1.2
1.2
—
—
—
0
0
9
41
2.21
1.37
1.2
1.2
—
—
—
0
0
6
23
2.62
1.37
1.5
1.7
—
—
—
0
0
5
17
2.96
1.36
6.8
3.2
200.60
209.65
u/l
—
5
17
6
24
2.51
1.30
1.5
1.7
—
—
—
0
0
16
91
1.78
1.30
2.2
2.1
15.30
16.60
%
—
9
43
19
114
1.69
1.29
1.7
1.9
—
—
—
0
0
96
785
1.27
1.28
1.2
1.3
7.37
11.10
u/ml
0.45
32
313
332
3070
1.18
1.25
2.9
3.1
—
—
—
0
0
6
25
2.41
1.24
1.0
3.4
—
—
—
0
0
29
196
1.50
1.24
1.9
1.9
—
—
—
0
0
9
45
2.02
1.23
1.4
1.2
0.90
1.50
nmol/l
—
9
40
6
26
2.32
1.19
1.2
1.7
—
—
—
0
0
12
64
1.89
1.18
1.0
1.1
—
—
—
0
0
13
73
1.80
1.11
1.4
1.6
—
—
—
0
0
19
120
1.60
1.09
3.3
1.7
—
—
—
0
0
14
81
1.75
1.09
5.3
3.2
4.12
4.39
e9/l
0.18
14
81
5
21
2.39
1.09
3.2
1.9
—
—
—
0
0
5
21
2.39
1.09
3.4
2.9
35.40
36.87
umol/l
—
5
15
11
59
1.88
1.08
1.4
1.4
0.56
0.55
nmol/l
0.06
11
54
13
74
1.77
1.07
1.4
1.6
—
—
—
0
0
13
74
1.77
1.07
1.4
1.6
—
—
—
0
0
7
33
2.13
1.06
1.4
1.6
—
—
—
0
0
15
90
1.68
1.05
1.5
1.5
—
—
—
0
0
21
138
1.54
1.04
1.6
1.4
266.67
286.15
ug/g
0.15
12
77
10
53
1.90
1.01
1.3
1.7
—
—
—
0
0
10
53
1.90
1.01
1.3
1.7
—
—
—
0
0
10
53
1.90
1.01
1.3
1.7
—
—
—
0
0
146
1279
1.19
1.01
5.8
3.7
0.00
0.01
estimate
0.69
52
435
11
61
1.82
0.99
1.9
1.9
31.35
16.90
ug/l
0.42
11
61
14
84
1.68
0.98
6.0
3.6
57.50
56.90
%
0.05
14
84
474
4562
1.19
0.95
20.4
12.7
84.31
82.27
ml/min/173m2
1.12
408
3771
201
1818
1.16
0.94
5.4
3.5
—
—
—
0
0
6
27
2.23
0.93
1.0
1.0
—
—
—
0
0
6
28
2.15
0.91
1.0
4.0
65.83
87.14
nmol/l
—
6
28
6
29
2.08
0.89
1.0
1.3
86.17
83.28
umol/l
—
6
29
16
103
1.57
0.88
5.3
3.8
41.33
27.18
mg/l
—
9
68
6
31
1.94
0.84
1.0
1.7
—
—
—
0
0
8
45
1.79
0.84
1.1
1.4
—
—
—
0
0
68
565
1.23
0.83
7.9
7.1
—
—
—
0
0
119
1043
1.18
0.83
5.4
3.7
1.02
1.02
kg/l
0.40
18
150
8
47
1.71
0.81
1.3
1.6
—
—
—
0
0
12
74
1.63
0.78
1.3
1.6
—
—
—
0
0
12
74
1.63
0.78
1.3
1.6
—
—
—
0
0
208
1912
1.13
0.76
5.4
4.9
2.14
2.93
ug/l
0.63
188
1722
12
75
1.61
0.75
1.3
1.6
—
—
—
0
0
5
26
1.93
0.70
1.8
1.8
—
—
—
0
0
5
26
1.93
0.70
1.8
1.8
—
—
—
0
0
17
118
1.45
0.70
15.8
6.5
105.47
105.16
mmol/l
0.11
17
108
5
27
1.86
0.68
1.6
1.5
1.39
1.01
g/l
—
5
27
5
27
1.86
0.68
1.0
1.6
—
—
—
0
0
5
27
1.86
0.68
1.0
1.6
—
—
—
0
0
7
43
1.64
0.67
1.1
1.1
—
—
—
0
0
7
44
1.60
0.65
1.1
1.1
—
—
—
0
0
5
29
1.73
0.64
1.0
1.6
3.40
2.35
u/field
—
5
21
26
204
1.29
0.55
11.0
5.1
1.69
1.60
%
0.25
26
192
16
118
1.37
0.50
1.4
1.4
—
—
—
0
0
16
118
1.37
0.50
1.4
1.4
—
—
—
0
0
16
119
1.35
0.48
1.4
1.4
—
—
—
0
0
16
119
1.35
0.48
1.4
1.4
—
—
—
0
0
7
47
1.50
0.47
1.1
1.0
—
—
—
0
0
43
503
0.84
0.47
2.7
4.4
78.22
29.08
ug/l
0.35
28
428
7
49
1.43
0.46
1.7
2.1
—
—
—
0
0
16
121
1.33
0.44
1.1
1.4
—
—
—
0
0
446
4565
0.91
0.44
4.3
3.9
1.43
1.29
mmol/l
3.05
400
4226
5
31
1.62
0.43
1.0
1.7
—
—
—
0
0
69
615
1.14
0.43
1.8
1.4
—
—
—
0
0
6
94
0.63
0.42
1.7
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
0.56
—
0
11
18
141
1.29
0.40
1.6
2.4
5941.50
3206.82
u/l
—
6
52
58
514
1.14
0.40
2.4
2.0
—
—
—
0
0
453
4433
1.09
0.38
6.5
5.6
40.93
39.80
mmol/mol
1.25
411
4141
5
36
1.39
0.38
2.2
3.0
14.40
59.58
u/ml
—
5
36
16
125
1.29
0.37
1.6
1.5
—
—
—
0
0
8
116
0.69
0.37
1.5
1.2
—
—
—
0
0
17
135
1.27
0.35
4.5
3.5
1.57
1.52
mg/l
0.10
17
125
91
839
1.10
0.33
2.5
3.0
2.45
2.44
mmol/l
0.27
84
736
478
4859
0.92
0.33
5.0
4.8
2.71
2.75
mmol/l
0.40
428
4507
522
5150
1.11
0.33
14.6
10.3
28.88
27.33
u/l
0.85
506
4990
63
571
1.12
0.32
2.6
2.2
—
—
—
0
0
7
57
1.23
0.29
1.3
3.5
3.03
3.66
nmol/l
—
7
57
468
4752
0.93
0.28
4.7
4.3
1.38
1.44
mmol/l
2.14
420
4411
17
140
1.22
0.27
1.8
1.4
363.14
275.61
miu/ml
—
7
67
8
64
1.25
0.27
1.6
1.5
—
—
—
0
0
8
65
1.23
0.27
1.0
1.1
—
—
—
0
0
8
65
1.23
0.27
8.3
4.7
380.13
366.32
umol/l
—
8
57
161
1536
1.07
0.27
4.2
4.2
21.06
21.32
%
0.07
76
724
9
74
1.22
0.25
1.1
1.4
—
—
—
0
0
471
4774
0.94
0.24
4.6
4.4
4.59
4.63
mmol/l
0.36
426
4457
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
5
43
1.16
0.21
1.0
1.3
1.88
2.93
ug/l
—
5
37
6
48
1.25
0.20
1.2
1.1
—
—
—
0
0
20
176
1.14
0.17
2.5
1.8
—
—
—
0
0
116
1113
1.05
0.17
3.4
2.9
0.70
0.77
ug/l
0.43
79
724
8
68
1.18
0.16
1.0
1.1
2.02
1.49
g/l
—
8
62
427
4221
1.04
0.15
27.2
16.5
15.09
14.91
%
0.24
422
4169
22
198
1.12
0.14
1.7
3.0
9.06
955.69
u/ml
0.75
16
171
81
843
0.95
0.12
1.7
1.5
—
—
—
0
0
25
232
1.08
0.10
2.8
2.0
—
—
—
0
0
135
1320
1.03
0.09
1.7
1.7
1.42
1.41
mmol/l
0.05
105
1111
6
54
1.11
0.09
3.0
3.5
—
—
—
0
0
7
64
1.09
0.08
1.3
1.1
—
—
—
0
0
7
67
1.05
0.08
1.0
1.1
—
—
—
0
0
22
235
0.93
0.07
1.0
1.0
—
—
—
0
0
39
373
1.05
0.07
3.2
2.8
64.71
68.18
ml/min/173m2
0.25
17
164
463
4653
0.98
0.06
5.0
4.4
6.09
5.95
mmol/l
0.93
412
4273
541
5393
1.03
0.06
33.7
20.5
39.85
40.45
%
1.34
511
5042
541
5393
1.03
0.06
33.1
20.4
249.29
247.14
e9/l
0.31
528
5268
15
139
1.08
0.05
1.4
1.4
—
—
—
0
0
13
120
1.09
0.05
1.8
1.5
—
—
—
0
0
541
5397
1.03
0.04
33.1
20.4
4.44
4.52
e12/l
3.09
524
5258
541
5399
1.02
0.03
33.3
20.5
134.14
136.62
g/l
2.93
532
5322
29
286
1.01
0.00
2.8
2.0
—
—
—
0
0
44
443
0.99
0.00
1.7
1.7
—
—
—
0
0
14
141
0.99
0.00
1.4
1.4
—
—
—
0
0
20
199
1.01
0.00
1.5
1.5
—
—
—
0
0
7
76
0.92
-0.00
2.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.1
—
82.78
—
0
9
9
91
0.99
-0.00
1.4
1.2
10.48
34.31
u/l
—
9
78
0
9
0.00
-0.00
0.0
6.0
—
7.41
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_GUILBAR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 2.186 [1.81, 2.63] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.473 |
During the follow-up period (1.1.1998 — 31.12.2019), 256 out of 1332 females with G6_GUILBAR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 1.876 [1.59, 2.21] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 391 out of 1622 males with G6_GUILBAR died.
Mortality risk
Mortality risk for people of age
years, who have G6_GUILBAR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.24% | 0.382% |
| 5 | 1.313% | 1.977% |
| 10 | 3.35% | 4.535% |
| 15 | 6.366% | 8.683% |
| 20 | 11.367% | 14.611% |
Relationships between endpoints
↥Index endpoint: G6_GUILBAR – Guillain-Barre syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data